Clinical Trial Update: Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients [Phase 3]

View source ↗

Summary

Results from a Phase 3 trial comparing regorafenib plus irinotecan versus regorafenib alone in metastatic colorectal cancer have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• Regorafenib (regorafenib)

Snippet

Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle | Conditions: Metastatic Colorectal Cancer (mCRC) | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-18